IBRANCE
Identification of Ibrance
| No description |
Google image searchProduct monograph
Active ingredient
palbociclib, 125 MG
DIN: 02493551
Dosage form(s): TABLET
Route(s) of administration: ORAL
Schedule: Prescription
Company: PFIZER CANADA ULC
Date: 21-SEP-2020
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01E — PROTEIN KINASE INHIBITORS (ATC, ATC/DDD)
- L01EF — Cyclin-dependent kinase (CDK) inhibitors (ATC, ATC/DDD)
- L01EF01 — PALBOCICLIB (ATC/DDD)
Reference brand drug: Ibrance
